Skip to main content
. 2008 Dec 18;100(3):419–428. doi: 10.1111/j.1349-7006.2008.01064.x

Figure 6.

Figure 6

Summarized data of the attachment assay of the effects of 10 ng/mL CCL2 in the absence (I‐2 and II‐2) or presence of CCL2‐specific antibody (CCL2 neutralization, I‐3 and II‐3) or anti‐ICAM‐1 antibody (I‐4 and II‐4) using breast cancer cell lines MCF‐7 (I) and MDA‐MB‐231 (II). The ordinate shows the normalized number of adherent carcinoma cells per field (×100). **P < 0.01, significantly different from 10 ng/mL CCL2‐mediated response or significantly different from each breast cancer cell.